Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Feb 06, 2023 1:00 PM - Feb 09, 2023 12:35 AM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Global Pharmacovigilance and Risk Management Strategies Conference

Stay current with the latest safety regulations from global health authorities and regulatory experts!

Session 8: Artificial Intelligence and Machine Learning Use in Patient Safety

Session Chair(s)

Jeremy  Jokinen, PhD, MS

Jeremy Jokinen, PhD, MS

Vice President and Head, Safety Evidence and Sciences

Bristol-Myers Squibb Company, United States

Examine the uses of machine learning and artificial intelligence in safety organizations globally. Both industry and regulatory perspectives will be included. Speakers will discuss applications in safety operations, surveillance (including literature surveillance) as well as topics related to regulation and updates from the AI/ML CIOMS working group.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe recent advances in the use of AI/ML with respect to safety surveillance
  • Determine the applicability of the use of AI/ML in your own organization
  • Recognize the progress of cross-industry working groups to increase understanding and contextualize the use of AI/ML in pharmacovigilance


Andrew  Bate, PhD, MA

How ML and Pharmacovigilance Interrelate Currently and How Symbiotic Progress Should Enable Real PV2.0

Andrew Bate, PhD, MA

GlaxoSmithKline, United Kingdom

Vice President, Head of Safety Innovation and Analytics

Nicole  Duarte Vigar Baker, PhD

Adoption of AI for Adverse Event Recognition from Unstructured Data

Nicole Duarte Vigar Baker, PhD

Biologit, Ireland


Niklas  Noren, PhD, MSc

Next-Generation Pharmacovigilance Analytics – Clustering and Semantic Representations of Adverse Events

Niklas Noren, PhD, MSc

Uppsala Monitoring Centre (UMC) , Sweden

Chief Science Officer

Phil  Tregunno

Regulating ML; How Precise Should We Be? A Perspective from the MHRA

Phil Tregunno

Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Deputy Director - Patient Safety Monitoring

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.